Abstract
HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].
| Original language | English |
|---|---|
| Pages (from-to) | 691-695 |
| Number of pages | 5 |
| Journal | Digestive Diseases and Sciences |
| Volume | 59 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 2014 |
Fingerprint
Keywords
- Hepatitis C
- Interferon
- Membrano-proliferative glomerulonephritis
- Ribavirin
ASJC Scopus subject areas
- Gastroenterology
- Physiology
Cite this
De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review). / Fabrizi, Fabrizio; Aghemo, Alessio; Moroni, Gabriella; Passerini, Patrizia; D'Ambrosio, Roberta; Martin, Paul; Messa, Piergiorgio.
In: Digestive Diseases and Sciences, Vol. 59, No. 3, 03.2014, p. 691-695.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis c (case study and literature review)
AU - Fabrizi, Fabrizio
AU - Aghemo, Alessio
AU - Moroni, Gabriella
AU - Passerini, Patrizia
AU - D'Ambrosio, Roberta
AU - Martin, Paul
AU - Messa, Piergiorgio
PY - 2014/3
Y1 - 2014/3
N2 - HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].
AB - HCV infects approximately 2-3 % of the global population and is a leading cause of end-stage liver disease and hepatocellular carcinoma. Antiviral treatment with pegylated interferon and ribavirin eradicates HCV in many patients, while 40-90 % of patients on pegylated IFN plus ribavirin have sustained viral clearance [1]. However, IFNbased therapy is limited by frequent and, at times, serious adverse effects which represent an important barrier to treatment delivery. In clinical trials, approximately 10-15 % of patients discontinue peg-IFN and ribavirin therapy due to adverse effects, but, in clinical practice, the rate of treatment interruption is probably higher. Combined antiviral therapy (conventional or pegylated IFN plus ribavirin) impacts most, if not all, organ systems. According to the KULDS Group, the rate of treatment discontinuation was 8.7 % (n = 250) in a total of 2,871 Japanese patients who had chronic HCV treated with peg- IFN a-2b and RBV [1].
KW - Hepatitis C
KW - Interferon
KW - Membrano-proliferative glomerulonephritis
KW - Ribavirin
UR - http://www.scopus.com/inward/record.url?scp=84896728698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896728698&partnerID=8YFLogxK
U2 - 10.1007/s10620-013-2959-4
DO - 10.1007/s10620-013-2959-4
M3 - Article
C2 - 24318802
AN - SCOPUS:84896728698
VL - 59
SP - 691
EP - 695
JO - Digestive Diseases and Sciences
JF - Digestive Diseases and Sciences
SN - 0163-2116
IS - 3
ER -